Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
ABEO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Abeona Therapeutics Inc.NASDAQ: ABEO
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $3.57M, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $6.99M. Over 3 fiscal years it compounded at +50.4% a year.
Context
- Cost of revenue amounted to 26.3% of revenue in FY2025.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly cost of revenue holds near $3.57M or moves back toward the trailing-twelve-month quarterly average of $1.75M.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.53M USD
- Year-over-year change
- -47.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.53M | -47.3% |
| FY2024 | 2024-12-31 | 2.91M | +81.1% |
| FY2023 | 2023-12-31 | 1.61M | +256.7% |
| FY2022 | 2022-12-31 | 450K | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How ABEO compares with its peers on the latest reported figures
- ABEO's LTM Mar 2026 cost of revenue of $6.99M is the 6th highest of the 10 companies compared; the peer median is $16.18M.
- Its year-over-year change of +800.8% is the highest of 6, against a peer median of -46.2%.
- Cost of revenue amounts to 48.1% of revenue for ABEO, versus a peer median of 44.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $68.13M | -46.2% | — | 186.7% | |
| LTM Mar 2026 | $58.03M | -9.7% | +1.8% | 25.5% | |
| LTM Mar 2026 | $21.94M | — | — | 77.7% | |
| LTM Mar 2026 | $17.11M | +85.4% | +27.3% | 848.5% | |
| LTM Mar 2026 | $16.18M | -62.1% | -87.7% | 22.8% | |
| LTM Mar 2026 | $6.99M | +800.8% | +50.4% | 48.1% | |
| LTM Mar 2026 | $4M | — | — | 8.8% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | -$101K | -104.8% | -1.1% | 44.9% | |
| Peer median (excluding ABEO) | $16.18M | -46.2% | +0.4% | 44.9% | |
Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3M | 1.41M | 3.5M | 0 | 5.82M |
| Cost of Revenue | 0 | 450K | 1.61M | 2.91M | 1.53M |
| Gross Profit | 3M | 964K | 1.9M | (2.91M) | 4.29M |
| Gross Margin | 100.0% | 68.2% | 54.1% | — | 73.7% |
| Research & Development | 38.73M | 28.97M | 31.09M | 34.36M | 26.81M |
| Selling, General & Admin | 21.64M | 17.26M | 19M | 29.85M | 65.03M |
| Operating Expenses | 92.84M | 51.88M | 49.03M | 61.3M | 93.74M |
| Depreciation & Amortization | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| EBITDA | (76.82M) | (34.38M) | (50.57M) | (56.62M) | 78.59M |
| EBITDA Margin | -2560.5% | -2431.6% | -1444.9% | — | 1350.3% |
| Operating Income | (89.84M) | (50.92M) | (47.14M) | (64.21M) | (89.45M) |
| Operating Margin | -2994.5% | -3600.8% | -1346.7% | — | -1536.9% |
| Interest Income | 40K | 431K | 2.12M | 4.25M | 5.56M |
| Interest Expense | 3.66M | 736K | 418K | 4.21M | 3.74M |
| Other Income / Expenses | 4.9M | 11.22M | (7.05M) | 477K | 160.73M |
| Income Before Tax | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.28M |
| Pre-Tax Margin | -2831.2% | -2807.4% | -1548.2% | — | 1224.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 100K |
| Net Income | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.18M |
| Net Margin | -2831.2% | -2807.4% | -1548.2% | — | 1223.1% |
| EPS (Basic) | (21.50) | (5.53) | (2.53) | (1.55) | 1.34 |
| EPS (Diluted) | (21.50) | (5.53) | (2.53) | (1.55) | 1.01 |
| Weighted Avg Shares | 3.94M | 7.86M | 21.38M | 41.05M | 52.95M |
| Weighted Avg Shares (Diluted) | 3.94M | 7.86M | 21.38M | 41.05M | 66.14M |
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.